Compare Ascendis Pharma A/S (ASND) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs LTC Properties Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while LTC Properties Inc trades at $39.06 (market cap $1.99B). The key difference: Ascendis Pharma A/S is far larger — about 8.9× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LTC | |
|---|---|---|
Market Cap | $17.74B | $1.99B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $40.36 |
52-Week Low | $163.32 | $33.98 |
Enterprise Value | $18.11B | $2.84B |
Dividend Yield | — | 5.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LTC Properties trades at $38.86, down 0.72% on the day, with a bullish technical signal from moving averages and a neutral RSI. The REIT shows strong profitability with a 39.09% net income margin and a P/E of 15.24. Recent acquisitions, including a $73 million SHOP portfolio expansion (Business Wire, 2026-07-08), highlight growth initiatives, while consistent monthly dividends of $0.19 provide income appeal.
The outlook is mixed: analyst consensus leans Hold (59.09%) amid recent earnings misses, but bullish technicals and strategic shifts to seniors housing offer upside. Risks include execution on SHOP transitions and debt levels, with net cash flow turning negative in 2026. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
